Merck KGaA investing €1B at headquarters site as part of 5-year work agreement

Merck kgaa
Merck KGaA has reached a new five-year agreement with 11,000 employees who work in and around its Darmstadt, Germany, headquarters site. (Merck KGaA)

Merck KGaA’s headquarters site in Darmstadt, Germany, is the pride of its international operations, and it intends to keep it that way. The German drug and materials maker says it has nailed down new work agreements with employees there and will invest €1 billion in the site.

Merck today said that the company management and the Joint Works Council at Darmstadt have signed a comprehensive agreement covering the 11,000 employees to secure its “future viability.” Merck said that with the deal, workers have bought into changes the company wants to make in its businesses. The agreement extends through 2025.

“With our investment commitment, we are permitting additional growth and are creating employment perspectives for tomorrow and beyond,” Kai Beckmann, the CEO of Performance Materials and the board member in charge of the Darmstadt site said in a statement. “Together with the employee representatives, we want to support the changes in our three business sectors here at the Darmstadt site in the best possible way.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Merck KGaA picks winners and losers as it streamlines EU production network, cutting 200 jobs

Michael Fletterich, chairman of the Works Council of Merck KGaA, said the two sides conducted intensive negotiations “and in some cases had strong debates” but that the agreement was both good for workers and the future of the company.

While €1 billion will be spent on projects and efforts across the site, some of the money will go towards a new plant to build membranes that among other uses go into filters for pharmaceutical production. Some also will be spent on a new Vocational and Advanced Training Center at the site. It said it currently has more than 500 apprentices in 22 vocational training occupations to feed its constant need for trained employees.

The work agreement covers 11,00 employees at Darmstadt and nearby Weiterstadt and Gernsheim in Germany. No employee cuts were announced but the company said it includes “a voluntary leave program and a bridge model for an early transition to retirement.”

The company last fall made some moves that cost 200 manufacturing jobs in Europe but benefited some sites, including Darmstadt.

Read more on

Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…

Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.